cell therapy patients with cardiomyopathy las-vegas, 2014
DESCRIPTION
Primary cardiomyopathies Genetic Mixed Acquired Secondary cardiomyopathies Infiltrative Storage Toxicity Endomyocardial Inflammatory Endocrine Cardiofacial Neuromuscular Nutritional Autoimmune Consequence of cancer therapy AHA classification for cardiomyopathiesTRANSCRIPT
![Page 1: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/1.jpg)
CELL THERAPY PATIENTS WITH
CARDIOMYOPATHY
Las-Vegas, 2014
![Page 2: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/2.jpg)
Cardiomyopathies – diseases of the myocardium with structural and functional abnormalities.
Dilated cardyomyopathy Hypertrophic cardyomyopathy Restrictive cardyomyopathy Arrhythmogenic right ventricular
cardyomyopathy /dysplasia
![Page 3: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/3.jpg)
Primary cardiomyopathiesGeneticMixedAcquired
Secondary cardiomyopathies
InfiltrativeStorageToxicityEndomyocardialInflammatoryEndocrineCardiofacialNeuromuscularNutritionalAutoimmuneConsequence of cancer therapy
AHA classification for cardiomyopathies
![Page 4: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/4.jpg)
*http://old.rosminzdrav.ru
Actuality*Population morbidity caused by:
Essential hypertension 191,8 – 100000Intracranial hemorrhage 26,8 – 100000 Cardiomyopathy 24,3 – 100000
![Page 5: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/5.jpg)
Aim: To evaluate the efficacy of systemic allograft multipotent mesenchymal stromal cells (MMSC) of the bone marrow for the treatment of dilated cardiomyopathy (DCM) of viral origin
![Page 6: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/6.jpg)
PatientsMain group
(cell therapy)Control group
(no cell)
Number 32 30Age 40,8 ± 5,2 41,3 ± 4,7
Men
Women
2012
1614
EF 25,3 ± 3,2 24,3 ± 4,8
![Page 7: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/7.jpg)
Informed consent was obtained for all patients
before participation in the study, and the study
protocol was approved by the Ethics Committee.
![Page 8: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/8.jpg)
Study Design echocardigraphy biochemical blood tests(inc. CEA, AFP,
PSA, CA19-9, CA125, CA15-3), 6-minute walk test, questionnaires SF-36, EQ-5D
Control point: before injection; 14 days and 1,3,6,12,24 months after the initial injection
![Page 9: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/9.jpg)
![Page 10: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/10.jpg)
Control of CellsViruses Herpes symp. I,II,VI
Cytomegalovirus,Epstein-Barr,HBV, HCV,HIV-1, HIV-2
Fungi Candida Albicans, Bacteria
Lactobacillus spp.,Mycoplasma spp.,Staphylococcus aureus., Steptococcus spp.,Bacteroides caccae,Bacteroides distasonis, merdae, Bacteroides eggerthii, stercoris, uniformis, Bacteroides fragilis group, Bacteroides fragilis BFT-toxin, Mobiluncus curtissi, Prevotella spp(bivia, disiens, melaninogenicus)SyphilisTPHA(Treponema pallidum pallidum)
![Page 11: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/11.jpg)
Criteria for Selection
-Safety cells-High viability(97%)-Expression of markers MMSC(CD34-,90+,105+, etc.)
![Page 12: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/12.jpg)
Method of injection cells- intravenous routeThe injection was carried out in the hospital from 3-5 days after pharmacological correction of the general condition.All patients completed the course of MMSC injections. The repeat injection was carried out at 30 ± 2.6 days. The total number of cell injected was 207 ± 5.8 million cells.
![Page 13: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/13.jpg)
RESULTS:Procedural characteristics:–No procedure-related complications during injections cells material–3 patients(10%) had mild fever(37,2 – 37,3OC)–No allergic reactions–No cancer–No myocardial infarction
![Page 14: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/14.jpg)
Echocardigraphy (Ejection Fraction,%)
Before injection
14 day after
1 mont
h
3mont
h
6mont
h
12mont
h
24mont
h
Main grou
p
27.9 ± 1.9
28.1 ± 1.6
30.3 ± 1.3
34.2 ± 0.7
34.8 ± 1.5
33.2 ± 2.9
28.8 ± 1.7
Control
group
28.2 ± 1.7
28.1 ± 1.1
27.6 ± 1.6
27.2 ± 0.7
28.5 ± 2.3
27.9 ± 1.9
27.2 ± 1.5
Main group – with cells Control group – no cells
![Page 15: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/15.jpg)
6-minute walk test
Basel
ine
1 mon
th
3mon
th
6mon
th
12mon
th
24mon
th
050
100150200250300350400450500
Main group Control group
Steps
![Page 16: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/16.jpg)
QuestionnaireHealth-related quality-of-life
instruments
![Page 17: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/17.jpg)
Baseline 1month 3month 6month 12month 24month010203040506070
РН МН РН(control) МН(control)
Score
PH – physical health MH – mental health
SF-36
![Page 18: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/18.jpg)
EQ-5D
Main(with cells)
Control(no cells)
0.720.740.760.780.8
0.820.84
Baseline1month3month6month12month24month
Index
![Page 19: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/19.jpg)
Hospitalizations
Duration(day)Periodicity per
year
0123456789
10
7
1
10
2
Main(with cells)
![Page 20: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/20.jpg)
Mortality
02468
1012
3
12
Main(with cells) Control(no cells)
Patient
![Page 21: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/21.jpg)
Take home message:
Injection of allogenic MMSC in patients with DCM after viral
myocardial damage is safety and efficacy
![Page 22: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/22.jpg)
Professor, MD Lishchuk Alexander Professor,MD Kornienko Andrey (Federal State “3rd Central Military Hospital named after A.A. Vishnevsky”, Ministry of Defence of the Russian Federation)
Professor, MD, Khadartsev Alexander(Federal State Budgetary Educational Establishment of Higher Professional Education “TULA STATE UNIVERSITY, Medical Institute”)
Professor, ScD, Saburina Irina Professor, ScD, Kolokoltsova Tamara(Institute of General Pathology and Pathophysiology, Russian Academy of Medical Science)
![Page 23: CELL THERAPY PATIENTS WITH CARDIOMYOPATHY Las-Vegas, 2014](https://reader036.vdocuments.net/reader036/viewer/2022081605/5a4d1aeb7f8b9ab05997aee1/html5/thumbnails/23.jpg)
Thank you for attention